Invivyd Inc/$IVVD
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Invivyd Inc
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Ticker
$IVVD
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
100
ISIN
US00534A1025
Website
Invivyd Inc Metrics
BasicAdvanced
$87M
-
-$1.19
0.41
-
Price and volume
Market cap
$87M
Beta
0.41
52-week high
$1.30
52-week low
$0.46
Average daily volume
1.9M
Financial strength
Current ratio
1.529
Quick ratio
1.146
Total debt to equity
1.651
Profitability
EBITDA (TTM)
-146.059
Gross margin (TTM)
93.32%
Net profit margin (TTM)
-389.00%
Operating margin (TTM)
-402.61%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-57.84%
Return on equity (TTM)
-122.69%
Valuation
Price to revenue (TTM)
2.369
Price to book
1.61
Price to tangible book (TTM)
1.61
Price to free cash flow (TTM)
-0.614
Free cash flow yield (TTM)
-162.88%
Free cash flow per share (TTM)
-118.33%
Growth
Earnings per share change (TTM)
-35.83%
3-year earnings per share growth (CAGR)
-23.19%
Invivyd Inc News
AllArticlesVideos
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
GlobeNewsWire·4 days ago
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus
GlobeNewsWire·1 month ago
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Invivyd Inc stock?
Invivyd Inc (IVVD) has a market cap of $87M as of June 30, 2025.
What is the P/E ratio for Invivyd Inc stock?
The price to earnings (P/E) ratio for Invivyd Inc (IVVD) stock is 0 as of June 30, 2025.
Does Invivyd Inc stock pay dividends?
No, Invivyd Inc (IVVD) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Invivyd Inc dividend payment date?
Invivyd Inc (IVVD) stock does not pay dividends to its shareholders.
What is the beta indicator for Invivyd Inc?
Invivyd Inc (IVVD) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.